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Human cystinuria-related transporter: Localization and func- Cystinuria (MIM 220100) is an autosomal recessive
tional characterization. inheritable disease caused by the defect of cystine and
Background. Cystinuria has been proposed to be an inher- basic amino acid transport in renal proximal tubules andited defect of apical membrane transport systems for cystine
small intestine [1]. The incidence of cystine crystalluriaand basic amino acids in renal proximal tubules. Although the
reported in Western countries and in Japan varied frommutations of the recently identified transporter BAT1/b0,1AT
have been related to nontype I cystinuria, the function and 15,000:1 to 50,000:1 [2, 3]. Even though the incidence
localization of human BAT1 (hBAT1)/b0,1AT have not been does not seem prominent, cystinuria is still an important
well characterized. disease because the patients suffer from recurrent neph-Methods. The cDNA encoding hBAT1 was isolated from
rolithiasis leading to severe renal dysfunctions for whichhuman kidney. Fluorescence in situ hybridization was performed
repeated therapies are imperative [4]. Three types ofto map the hBAT1 gene on human chromosomes. Tissue distri-
bution and localization of expression were examined by North- classic cystinuria (I, II, and III) have been described [5].
ern blot and immunohistochemical analyses. hBAT1 cDNA In type I heterozygotes, urine amino acid content is
was transfected to COS-7 cells with rBAT cDNA, and the
within the normal range, while type II and type III het-uptake and efflux of 14C-labeled amino acids were measured
erozygotes exhibit high or moderate levels of hyperex-to determine the functional properties. The roles of protein
kinase-dependent phosphorylation were investigated using in- cretion of cystine and basic amino acids [5]. In contrast
hibitors or activators of protein kinases. to type I and type II homozygotes, type III homozygotes
Results. The hBAT1 gene was mapped to 19q12-13.1 on the show an increase in plasma cystine levels following oral
human chromosome, which is the locus of nontype I cystinuria.
cystine administration.hBAT1 message was expressed predominantly in kidney. hBAT1
The discovery of a type II membrane glycoproteinprotein was localized in the apical membrane of proximal tu-
bules in human kidney. When expressed in COS-7 cells with rBAT (related to b0,1 amino acid transporter; also called
a type II membrane glycoprotein rBAT (related to b0,1–amino D2 by Wells and Hediger [6]) was a breakthrough in our
acid transporter), hBAT1 exhibited the transport activity with understanding of the molecular basis of cystinuria [6–8].the properties of amino acid transport system b0,1, which trans-
rBAT induces the transport activity for cystine as wellported cystine as well as basic and neutral amino acids presum-
as basic and neutral amino acids with the propertiesably via a substrate exchange mechanism. BAT1-mediated
transport was reduced by the protein kinase A activator and of amino acid transport system b0,1 when expressed in
enhanced by the tyrosine kinase inhibitor. Xenopus oocytes [6, 7, 9, 10]. System b0,1 is an amino
Conclusions. hBAT1 exhibited the properties expected for
acid transport system originally identified in mousea transporter subserving the high-affinity cystine transport sys-
blastocyst, which transports neutral and basic aminotem in renal proximal tubules. The hBAT1 gene was mapped
to the locus of nontype I cystinuria, confirming the involvement acids in a Na1-independent manner [11]. rBAT has, how-
of hBAT1 in cystinuria. ever, been regarded as a transport activator or modula-
tor, not a transporter itself, because it possesses only a
single membrane-spanning domain, which is unusual forKey words: amino acid transporter, renal proximal tubule, kidney
stone, hBAT1 gene, inherited disease, nephrolithiasis. transporters, and also because it dose not induce amino
acid transport when expressed in COS-7 cells, in spiteReceived for publication June 20, 2000
of its activity exhibited in Xenopus oocytes [6, 7, 12, 13].and in revised form December 6, 2000
Accepted for publication December 11, 2000 By now, several distinct mutations have been found in
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Fig. 1. Structural features of human BAT1. (A) Sequence alignment of human and rat BAT1. The deduced amino acid sequence of hBAT1 is
shown to be aligned with rat BAT1 [25]. Dots in the rat sequence indicate amino acids that are identical to the human sequence. Predicted
membrane-spanning regions numbered 1 to 12 are shown by lines above the sequences. A potential tyrosine kinase-dependent phosphorylation
site is located at residue 99 (indicated by #). Protein kinase C (PKC)-dependent phosphorylation sites are predicted on the human sequence at
residues 51, 169, 345, and 399, among which those at residues 345 and 399 are predicted to be located intracellularly (indicated by an asterisk).
A potential cAMP-dependent phosphorylation site is located at residue 350 (indicated by 1). (B) A topological model of hBAT1 and rBAT.
Putative tyrosine phosphorylation site (Y99) and cAMP-dependent phosphorylation site (T350) are indicated in hBAT1. hBAT1 and rBAT are
proposed to be linked via a disulfide bond between C144 of hBAT1 and C114 of rBAT. Six N-liked glycosylation sites are predicted in the
extracellular domain of rBAT.
It has therefore been proved that the genetic defect in nuria, which leads to the impaired amino acid reabsorp-
tion [23]. Recently, we and others have identified a trans-the rBAT function is responsible for the type I cystinuria.
The rBAT mutations have, however, not been found porter activated by rBAT [25–27]. The transporter
designated as BAT1 (rat) [25] or b0,1AT (human andin patients with nontype I (type II and type III) cystinuria
[23]. In addition, linkage analysis studies have mapped mouse) [26, 27] belongs to the family of amino acid
transporters associated with type II membrane glycopro-the gene(s) for nontype I cystinuria to 19q12-13.1, which
is distinct from the locus of rBAT gene (2p16.3-21) [24]. teins [25–35] and forms a heterodimeric complex with
rBAT to express its function. Although rat and mouseTherefore, it has been speculated that the transporter(s)
activated by rBAT would be defective in nontype I cysti- BAT1/b0,1AT has been shown to induce the system b0,1
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Fig. 1. (Continued)
activity when expressed with rBAT, the function of hu- were performed as described previously [33, 37]. The
cDNA in positive lZipLox phages was rescued into plas-man BAT1 (hBAT1)/b0,1AT has not been well charac-
mid pZL1 by in vivo excision following manufacturer’sterized [25–27]. In the present study, to evaluate the
instructions (Life Technologies). The cDNA was se-role of BAT1/b0,1AT in renal amino acid reabsorption in
quenced in both direction by the dye terminator cyclehumans and also to assess the significance of its functional
sequencing method (Perkin Elmer, Norwalk, CT, USAdefect in cystinuria, we have characterized functional
and Applied Biosystems, Foster City, CA, USA). Theproperties of hBAT1 and determined its localization in
membrane-spanning regions of proteins were predictedhuman kidney. We also demonstrate the regulation of
on the amino acid sequences based on the SOSUI algo-the transporter function by protein phosphorylation.
rithm [38].
To isolate human rBAT cDNA, the human kidney
METHODS cDNA library was also screened using a cDNA probe
for rat D2/rBAT provided by Dr. Matthias A. HedigercDNA cloning
(Brigham and Women’s Hospital and Harvard MedicalThe cDNA for a human expressed sequence tag (EST;
School, Boston, MA, USA). The isolated cDNA (2318GenBanke/EBI/DDBJ accession no. R07056), which
bp) was confirmed to encode human rBAT (hrBAT) byshows nucleotide sequence similarity to rat BAT1, was
nucleotide sequencing (GenBanke/EBI/DDBJ acces-obtained from the Integrated Molecular Analysis of Ge-
sion no. AB033549).nomes and Their Expression (IMAGE clone No.
126710). The 484 bp cDNA fragment was amplified from Chromosome localization
the IMAGE clone using polymerase chain reaction Fluorescence in situ hybridization (FISH) detection
(PCR) with synthetic oligonucleotide primers 59-ACCT was performed as described elsewhere [39, 40]. Full
GCCTTTGGCCATTATC-39 and 59-ACTACGGGCA cDNA insert of hBAT1 was used as a probe. Chromo-
CCTTGATA-39 (corresponding to nucleotides 30 to 49 somes were stained before analysis with propidium io-
bp and 494 to 513 bp of the nucleotide sequence of the dide as counterstaining and 4,6-diamino-2-phenylindole
cDNA insert of IMAGE clone no. 126710). The cDNA (DAPI) for chromosome identification. FISH signals and
fragment was labeled with [32P]dCTP (T7QuickPrime; the DAPI banding pattern were recorded separately by
Amersham Pharmacia Biotech, Tokyo, Japan) and used taking photographs, and the assignment of the FISH
for screening a nondirectional human kidney cDNA li- mapping data with chromosomal bands was achieved by
brary. The library was prepared from human kidney superimposing FISH signals with DAPI banded chromo-
poly(A)1RNA (Clonetech, Palo Alto, CA, USA) using somes.
Superscript Choice System (Life Technologies, Grand
Northern analysisIsland, NY, USA) [36]. The synthesized cDNA was li-
gated to lZiplox EcoRI arms (Life Technologies). Northern analysis was performed using Human Multi-
ple Tissue Northern (MTNe) blot (Clonetech). The cDNAScreening the library and the isolation of positive plaques
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fragment used for screening the cDNA library (corre- a 24-well plate (2 3 105/well) in fresh culture media.
Amino acid uptake measurements were performed at 48sponding to 840 to 1323 bp of hBAT1 cDNA) was labeled
with [32P]dCTP (T7QuickPrime; Amersham Pharmacia hours after transfection.
Biotech) and used as a probe. Hybridization and the
Amino acid uptake measurementsfollowing washing of the filter were performed as de-
scribed in the manufacturer’s instructions (Clonetech). After the removal of growth medium, the cells were
washed twice with regular uptake solution [Dulbecco’s
Immunohistochemistry modified phosphate-buffered saline (PBS) supplemented
with 5 mmol/L glucose] and preincubated for 10 minutesThe polyclonal antibody raised against the synthetic
oligo peptide corresponding to amino acid residues 474 at 378C [25]. Then the medium was replaced by the regular
uptake solution containing 14C-amino acids. Amino acidto 487 of rat BAT1 previously used to localize BAT1
protein in rat kidney was used for the immunohistochem- uptake was terminated by removing uptake medium fol-
lowed by washing three times with ice-cold regular up-ical analysis of human kidney [25]. Only a single amino
acid was altered in hBAT1 in the region of peptide take solution. Then cells were solubilized with 0.1 N
NaOH, and radioactivity was counted. For Na1-free up-against which the polyclonal antibody was produced
(Glu 484 for hBAT1 vs. Lys 484 for rat BAT1). Antisera take solution, NaCl in the modified Hank’s solution was
replaced by choline chloride. For the uptake measure-were affinity purified as described elsewhere [41]. Three
micrometer paraffin sections of nephrectomized human ments, the regular uptake solution was used unless other-
wise indicated.kidney were processed for light microscopic immunohis-
tochemical analysis as described previously [36]. The re- For the inhibition experiments, the uptake of [14C]l-
cystine (50 mmol/L) was measured in the presence of 5nal tissue was obtained from a tumor patient and ap-
proved by the Kyorin University Institutional Research mmol/L nonlabeled amino acids and amino acid-related
compounds. The values were expressed as a percentageBoard (IRB) to be used for medical study. Sections were
dewaxed, rehydrated, and treated with 10% H2O2 for of the control cystine uptake in the absence of inhibitors.
Km and Vmax of the amino acid substrates were deter-10 minutes to eliminate endogenous peroxidase activity.
Then the sections were incubated with affinity-purified mined using the Eadie-Hofstee equation based on
hBAT1-mediated amino acid uptakes measured at 5, 10,anti-BAT1 antibody (1:2000) overnight at 48C [25]. There-
after, they were treated with Envision (1) rabbit peroxi- 30, 50, 100, 300, 500, and 1000 mmol/L. The hBAT1-
mediated amino acid uptakes were calculated as differ-dase (Dako, Carpinteria, CA, USA) for 30 minutes. To
detect immunoreactivity, the sections were treated with ences between the means of uptakes of the COS-7 cells
transfected with hBAT1 and hrBAT cDNAs and thosediaminobenzidine (0.8 mmol/L). To verify the specificity
of immunoreactions by absorption experiments, the tis- of the mock-transfected controls.
sue sections were treated with the primary antibodies in
Efflux measurementthe presence of antigen peptides (50 mg/mL) [25].
For the efflux measurement, 14C-labeled l-leucine was
Functional expression preloaded by incubating COS-7 cells transfected with
hBAT1 and hrBAT cDNAs or mock-transfected con-cDNAs for hBAT1, human 4F2hc (h4F2hc: Gen-
Banke/EBI/DDBJ accession no. AB018010), and hBAT trols in Dulbecco’s PBS containing 100 mmol/L [14C]l-
leucine (2 mCi/mL) for 30 minutes. The cells were thenwere subcloned into the mammalian expression vector
pcDNA3.1(1) (Invitrogen, Carlsbad, CA, USA) [25]. washed five times with ice-cold Dulbecco’s PBS and incu-
bated in the uptake solution containing or not containingFor functional expression, these plasmids were solely
transfected or cotransfected to COS-7 cell (RIKEN Cell nonradiolabeled l-cystine (100 mmol/L). The radioactivi-
ties in the medium and the remaining radioactivity inBANK, Saitama, Japan) transiently using LIPOFEC-
TAMINEe 2000 Reagent (Life Technologies) following the cells were measured at 2, 5, 10, and 30 minutes. The
values were expressed as the percentage of radioactivitythe manufacturer’s instructions with minor modifica-
tions. COS-7 cells were maintained in Dulbecco’s modi- [radioactivity of medium/(radioactivity of medium 1 ra-
dioactivity of the cells) 3 100%].fied Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum. For transfection, 20 mg of plasmids
Effect of protein kinaseswere diluted into 1 mL DMEM without serum and mixed
with 60 mL LF2000 reagent diluted in 1 mL DMEM To evaluate the effect of intracellular phosphorylation
on hBAT1-mediated amino acid uptake, COS-7 cellswithout serum followed by incubating for 30 minutes at
room temperature. The mixture was applied to COS-7 transfected with hBAT1 and hrBAT cDNAs and mock-
transfected controls were treated with a protein kinasecells maintained in a tissue culture dish (90 mm diameter)
with 70 to 90% confluence. At 24 hours after transfec- A (PKA) activator [dibutylyl adenosine 39,59-cyclic mono-
phosphate (db-cAMP)], PKA inhibitor (H-89), proteintion, the transfected cells were collected and seeded on
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Fig. 2. Diagram of fluorescence in situ hybridization (FISH) mapping
result for hBAT1. (A) Example of FISH mapping of probe hBAT1.
The left panel shows the FISH signals on human chromosome; the
right panel shows the same mitotic figure stained with 4,6-diamino-2-
phenylindole (DAPI) to identify human chromosome 19. (B) Each dot
represents double FISH signals detected on human chromosome 19.
c
Fig. 3. Tissue distribution and localization of expression. (A) High
stringency Northern hybridization analysis of poly(A)1RNA from hu-
man tissues using a probe for hBAT1. A single hybridization band at 1.9
kb was detected in the kidney and the liver. (B) Immunohistochemical
analysis of human kidney using an anti-BAT1 antibody. The BAT1
immunoreactivity was localized on the apical membrane of the proximal
tubules (arrows). (Upper) Low-magnification view of the renal cortex
(scale bar, 150 mm). (Lower) High-magnification view of proximal con-
voluted tubules (scale bar, 20 mm).
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Fig. 4. Functional expression of hBAT1 in
COS-7 cells. (A) The functional association of
hBAT1 and hrBAT. The uptake of [14C]l-cys-
tine (100 mmol/L) was measured on “mock”
transfected COS-7 cells and COS-7 cells trans-
fected with hrBAT, h4F2hc, hBAT1, both
h4F2hc and hBAT1, or both hrBAT and
hBAT1. The cotransfection of hBAT1 and
hrBAT resulted in the large uptake of [14C]l-
cystine. (B) Na1 dependence of hBAT1-medi-
ated [14C]l-cystine uptake. The uptake of
[14C]l-cystine (100 mmol/L) was measured in
the regular-uptake solution (labeled as “NaCl”)
and in Na1-free uptake solution (labeled as
“choline Cl”). [14C]l-cystine uptake was not
altered by the removal of Na1.
kinase C (PKC) activator [phorbol 12-myrystate 13-ace- found a 95 bp nucleotide deletion in the 59-untranslated
tate (PMA)], or a PKC inhibitor (staurosporine; Wako, region of hBAT1 corresponding to 66 to 160 bp of the
Osaka, Japan) for 30 minutes in the preincubation solution b0,1AT nucleotide sequence (GenBanke/EBI accession
(the standard uptake solution containing protein kinase- AF141289). The hBAT1 also exhibited a similarity to
activators or inhibitors and 0.1% DMSO) [42–44]. The rat BAT1 (87% identity at the amino acid level) [25].
pretreatment time was fixed at 30 minutes because the As shown in Figure 1A, 12 transmembrane regions were
effects of pretreatment were more predominant at 30 predicted on the hBAT1 amino acid sequence. There is
minutes for each compound in preliminary experiments a conserved cysteine residue (hBAT1 amino acid residue
where they were compared at 30 and 60 minutes. Then, 144) in the putative extracellular loop between predicted
the preincubation solution was replaced by the standard transmembrane domains 3 and 4, through which hBAT1
uptake solution containing [14C]l-cystine (100 mmol/L) is predicted to be associated with rBAT (Fig. 1B) [45].
without the activators or inhibitors, and the uptake of A tyrosine kinase-dependent phosphorylation site was
radioactivity was measured for two minutes. predicted at residue 99 in the putative intracellular loop
For the uptake measurements, four wells were used between predicted transmembrane domains 2 and 3 (Fig.
for each data point. Each data point in the figures repre-
1). PKC-dependent phosphorylation sites were predicted
sents the mean 6 SEM of the uptake values (N 5 4)
on the human sequence at residues 51, 169, 345 and[25]. To confirm the reproducibility of the results, three
399, among which those at residues 345 and 399 wereseparate experiments were performed for each measure-
predicted to be located intracellularly. A potential cAMP-ment using different batches of COS-7 cell transfectants,
dependent phosphorylation site was located at residueexcept for the Km and Vmax determinations. The results of
350 (Fig. 1).the representative experiments are shown in the figures.
Chromosome localization of the hBAT1 gene
RESULTS Under the condition used, the efficiency of the FISH
Structural features of hBAT1 detection was approximately 71% for this probe (among
100 checked mitotic figures, 71 of them showed hybrid-A cDNA clone with a 1664 bp insert was isolated from
ization signals on one pair of chromosomes). Since thea human kidney cDNA library. It contained an open
DAPI banding was used to identify the specific chromo-reading frame from nucleotides 89 to 1552 encoding a
some, the assignment between signals from the probeputative 487 amino acid protein, designated as hBAT1
and the long arm of chromosome 19 was obtained (Fig.(human b0,1-type amino acid transporter 1). Although
2A). The detailed position was determined based on thethe deduced amino acid sequence of hBAT1 was identi-
cal to that of b0,1AT reported by Palacin et al [26], we summary from 10 photographs. Therefore, the hBAT1
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gene was mapped to human chromosome 19, region q12-
q13.1 (Fig. 2).
Tissue distribution and localization of expression
Northern blot analysis detected 1.9 kb hBAT1 message
in the kidney at a high level. A weaker message was de-
tected in the liver (Fig. 3A). In the immunohistochemical
analysis of human kidney tissues, hBAT1 immunoreactiv-
ity was demonstrated to be localized in the apical mem-
brane of proximal tubules (Fig. 3B). The immunoreactiv-
ity was stronger in proximal convoluted tubules than in
proximal straight tubules. In the absorption experiments
in which the tissue sections were treated with the primary
antibodies in the presence of antigen peptides, the immu-
nostaining was not detected, confirming the specificity of
the immunoreactions (data not shown).
Functional expression in COS-7 cells
Because of the difficulty in evaluating amino acid
transport mediated by hBAT1 in Xenopus oocytes,
where endogenous transporters activated by rBAT are
expressed abundantly [6, 7], COS-7 cells were used for
the functional characterization of hBAT1. As shown in
Figure 4A, the coexpression of hBAT1 with hrBAT, not
with h4F2hc, resulted in a marked [14C]l-cystine uptake.
When hBAT1, hrBAT, or h4F2hc was solely expressed,
significant [14C]l-cystine uptake was not detected com-
pared with mock-transfected COS-7 cells. Therefore, for
all of the following experiments, to determine the func-
tional properties of hBAT1, hBAT1 was coexpressed
with hrBAT in COS-7 cells. Fig. 5. Kinetic properties of hBAT1-mediated transport. (A) Time
course of hBAT1-mediated [14C]l-cystine uptake. The uptake of [14C]l-Figure 5A shows that [14C]l-cystine (100 mmol/L) up-
cystine (100 mmol/L) was measured for 0, 2, 5, 10, 20, 40, and 60 minutestake into COS-7 cells coexpressing hBAT1 and hrBAT and plotted against the incubation time. (B) Concentration dependence
was linearly dependent on an incubation time up to five of hBAT1-mediated [14C]l-cystine uptake. The BAT1-mediated [14C]l-
cystine uptake was measured at 5, 10, 30, 50, 100, 300, 500, and 1000minutes. In the following experiments, therefore, uptakes
mmol/L for two minutes. The cystine uptake was saturable and fittedwere measured for two minutes, and the values were to the Michaelis-Menten curve. (Inset) Eadie-Hofstee plot of the [14C]l-
expressed as pmol/mg protein/min. As shown in Figure cystine uptake on which Km and Vmax values were determined.
4B, hBAT1-mediated [14C]l-cystine uptake was not al-
tered by the removal of Na1 from the uptake solution,
indicating that the transport is Na1 independent. hBAT1- stereoselective nature of the transports. System A-selec-
mediated [14C]l-cystine uptake was saturable and fol- tive inhibitor a-(aminomethyl)isobutyric acid (MeAIB)
lowed the Michaelis-Menten kinetics with Km and Vmax and system l-selective inhibitor 2-aminobicyclo-(2,2,1)-
values of 296 6 35.2 mmol/L and 3243 6 389 pmol/mg heptane-2-carboxylic acid (BCH) exhibited no or little
protein/min (mean 6 SEM of 3 separate experiments; inhibitory effects on [14C]l-cystine uptake. Consistent
Fig. 5B), respectively. with the inhibition experiments, 14C-labeled l-cystine,
l-lysine, l-arginine, and l-ornithine showed high levels of
Substrate selectivity of the transport uptake. Neutral amino acids were transported at a lower
Substrate selectivity of hBAT1 was at first examined rate. The uptake values for glycine, proline, and acidic
by inhibition experiments in which 50 mmol/L [14C]l- amino acids were particularly low. The Km and Vmax val-
cystine uptake was measured in the presence of 5 mmol/L ues of hBAT1 for l-cystine, l-lysine, l-arginine, l-orni-
nonlabeled amino acids. As shown in Figure 6A, the cys- thine, and l-leucine are shown in Table 1.
tine uptake was inhibited by l-isomers of basic and neutral
Amino acid efflux mediated via hBAT1amino acids, but not by acidic amino acids. d-isomers of
basic amino acids were less effective in the inhibition of The efflux of preloaded [14C]l-leucine was measured
in the presence or absence of l-cystine in the medium.[14C]l-cystine uptake compared with l-isomers, indicating
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Fig. 6. Substrate selectivity of hBAT1-medi-
ated transport. (A) Inhibition profile of hBAT1-
mediated [14C]l-cystine uptake. The hBAT1-
mediated [14C]l-cystine uptake (50 mmol/L)
was measured in the presence of 5 mmol/L
nonlabeled amino acids except l-cystine (500
mmol/L). The values were expressed as a per-
centage of the control [14C]l-cystine uptake
(654 6 60 pmol/mg protein/min) in the ab-
sence of inhibitors [“(–)”]. The l-cystine up-
take was highly inhibited by basic and neutral
amino acids. Abbreviations are: CssC, l-cys-
tine; BCH, 2-aminobicyclo(2,2,1)-heptane-2-
carboxylic acid; MeAIB, a-(aminomethyl)iso-
butyric acid. (B) hBAT1-mediated amino acid
uptake. The hBAT1-mediated uptake was
measured at 10 mmol/L of radiolabeled amino
acids. Cystine and basic and neutral amino
acids were transported by hBAT1.
As shown in Figure 7A, extracellularly applied l-cystine
(100 mmol/L) enhanced the efflux of preloaded [14C]l-
Table 1. Kinetic parameters of amino acid substrates leucine in the COS-7 cells coexpressing hBAT1 and
Km hrBAT, whereas such an enhancement was not detected
Amino acid mmol/L Vmax in mock transfected cells (Fig. 7B), indicating the trans-
l-Cystine 296a (1.00) stimulation of hBAT1-mediated amino acid efflux.
l-Lysine 394 1.01
l-Arginine 108 0.65
l-Ornitine 195 0.58 Effect of protein kinase-dependent phosphorylation
l-Leucine 107 0.30
Treatment with the PKA activator db-cAMP decreased
The Km and Vmax values were determined as described in the Methods section. hBAT1-mediated [14C]l-cystine uptake in a dose-depen-These data are based on the results from five separate experiments using different
batches of COS-7 cells transfected with hBAT1 and hrBAT. In each experiment, dent manner (Fig. 8A). As shown in Figure 8B, the effect
l-cystine uptake levels were measured to compare the Vmax values between
of db-cAMP (150 mmol/L) was diminished by the specificexperiments. Vmax values for each amino acid were normalized to that for l-cystine
in the same experiment. inhibitor H-89 (0.1 mmol/L) at a concentration that dida The Km value for l-cystine is the mean of three measurements (mean 6 SEM 5
296 6 35.2 mmol/L) not affect the cystine transport by itself. Neither PKC
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Mb interval between microsatellite marker loci C17 A
and D19S874 on human chromosome 19 [26]. In this study,
FISH mapping was performed on human chromosomes
using hBAT1 cDNA as a probe. This revealed the single
locus for hBAT1 gene to be located at 19q12-13.1 (Fig.
2), exactly the same locus as that for nontype I cystinuria
as determined by linkage analysis [24], thus confirming
the involvement of hBAT1 in nontype I cystinuria.
It has been proposed that cystinuria is caused by the
inherited defect of apical membrane high-affinity trans-
porters responsible for the reabsorption of cystine and
basic amino acids from the glomerular filtrate in renal
proximal tubules [12, 23, 46]. The immunohistochemical
analysis in the present study in fact demonstrate that
hBAT1 protein exists in the apical membrane of proxi-
mal tubules in the human kidney (Fig. 3B). In rat kidney,
we previously showed that BAT1 protein coexists with
rBAT protein in the apical membrane of the proximal
tubules [25]. In human kidney, hBAT1 is proposed to
be colocalized with rBAT in the apical membrane of the
proximal tubules. Northern blot studies also detected
hBAT1 mRNA in human liver. This is interesting be-
cause it was previously reported that rBAT message is
expressed in human liver but not in rat liver. Therefore,
we propose that the heterodimeric complex composed
of hBAT1 and rBAT contributes to the amino acid trans-
port in human liver.
In the present study, we performed a functional char-
acterization of hBAT1. Consistent with rat and mouse
BAT1/b0,1AT, hBAT1 required rBAT for its functional
expression (Fig. 4A) [25, 27]. When expressed with rBAT
in COS-7 cells, hBAT1 induced Na1-independent trans-
port of cystine as well as basic and neutral amino acids.
Fig. 7. Efflux of [14C]L-leucine mediated by hBAT1. The time course
The report by Palacin et al only showed that the coex-of [14C]l-leucine efflux from the COS-7 cells coexpressing hBAT1 and
hrBAT (A) and mock-transfected COS-7 cells (B). The cells were pression of human b0,1AT and rBAT resulted in an in-
preloaded with [14C]l-leucine as described in the Methods section. Both duction of the transport activity for arginine [26]. The
the radioactivity of the uptake solution and the remaining radioactivity
results from the present investigation indicate that hBAT1in the cells were measured at 2, 5, 10, and 30 minutes. The values were
expressed as a percentage of total radioactivity loaded into the cells is a transporter subserving the amino acid transport sys-
(Methods section). The efflux of [14C]l-leucine from the COS-7 cells tem b0,1, which accepts cystine as well as basic and neu-
coexpressing hBAT1 and hrBAT was higher in the presence of l-cystine
tral amino acids in a Na1-independent manner (Figs.(100 mmol/L) in the medium (d) than in the absence of cystine (s;
A). In mock transfected COS-7 cells, there was no difference in the 4B and 6), consistent with rat and mouse BAT1/b0,1AT
efflux of preloaded [14C]l-leucine, regardless of the presence (d) or [25, 27]. Km values for cystine and basic amino acids wereabsence (s) of cystine in the medium (B).
between 100 and 400 mmol/L (Table 1), still regarded as
high-affinity transport numbers in agreement with the
cystine transport system responsible for the reabsorption
of cystine at the proximal tubules [46, 47].activator PMA nor its inhibitor staurosporine had sig-
Based on the obligatory exchange properties charac-nificant effects on hBAT1-mediated [14C]l-cystine up-
terized for the Xenopus oocyte-endogenous system b0,1take (Fig. 9). The tyrosine kinase inhibitor genistein dose-
activated by the expression of rBAT, Palacin et al pro-dependently increased the hBAT1-mediated [14C]l-cystine
posed that cystine and basic amino acids are reabsorbeduptake (Fig. 10).
via system b0,1 in exchange for substrate amino acids in
renal proximal tubules [48]. In agreement with this the-
DISCUSSION ory, we show that hBAT1-mediated efflux of preloaded
Based on the YAC library and BAC contig screening, 14C-leucine was trans-stimulated by the extracellularly
applied cystine (Fig. 7). We believe that the system b0,1–Palacin et al confined the BAT1/b0,1AT gene to a 1.3
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Fig. 8. Inhibition of hBAT1-mediated trans-
port by PKA activation. (A) hBAT1-mediated
[14C]l-cystine uptake (100 mmol/L) was mea-
sured after the preincubation of cells with the
PKA activator db-cAMP (30, 100, 150, and
300 mmol/L). Values were expressed as a per-
centage of control [14C]l-cystine uptake (1309 6
74 pmol/mg protein/min) measured after the
preincubation of cells with 0.1% DMSO with-
out db-cAMP (h). Treatment with db-cAMP
significantly decreased the hBAT1-mediated
[14C]l-cystine uptake in a dose-dependent
manner. The asterisks indicate statistical sig-
nificance (*P , 0.05; **P , 0.01). (B) The
effect of a PKA-specific inhibitor, H-89, was
examined. The db-cAMP (150 mmol/L)-elic-
ited decrease in the hBAT1-mediated [14C]l-
cystine uptake (100 mmol/L) was suppressed
by H-89 (0.1 mmol/L). H-89 (0.1 mmol/L) by
itself did not exert a significant effect on the
hBAT1-mediated cystine uptake.
Fig. 9. Effect of PKC activation on hBAT1-
mediated cystine transport. The effect of PKC
activator PMA (A) and that of inhibitor staur-
osporine (B) were examined. Values were ex-
pressed as a percentage of control [14C]l-cys-
tine uptake (1378 6 126 pmol/mg protein/min)
measured after the preincubation of cells with
0.1% DMSO without PMA or staurosporine
(STS) (h). The treatment with PMA (0.1, 0.3,
1.0, and 3.0 mmol/L) or STS (0.1, 0.3, 1.0, and
3.0 mmol/L STS) had no significant effect on
hBAT1-mediated [14C]l-cystine uptake (100
mmol/L).
transporter composed of hBAT1 and rBAT also func- patients are usually cystine and basic amino acids, and do
not include neutral amino acids. This is because neutraltions as an amino acid exchanger in human proximal
tublules to reabsorb cystine and basic amino acids effi- amino acids are reabsorbed by the apical membrane
system B0, which is Na1 dependent and specific to neutralciently from the luminal fluid in human proximal tubules.
As already indicated, system b0,1 transports not only amino acids [49]. This powerful neutral amino acid trans-
port system is also predicted to reabsorb neutral aminocystine and basic amino acids but also neutral amino
acids [11]. Consistent with this observation, we show that acids, which appear in the luminal fluid via system b0,1
in exchange for the reabsorption of cystine and basicthe substrates for hBAT1 include neutral amino acids.
However, the amino acids excreted in urine in cystinuric amino acids.
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itor genistein increased the hBAT1-mediated 14C-cystine
uptake, and suggest that hBAT1 is negatively regulated
by tyrosine-phosphorylation.
The physiological significance of the phosphorylation-
dependent regulations of the amino acid transporters in
renal proximal tubules has not been clarified yet. It can
be speculated, however, that hormonal stimulation of
tubular epithelial cells might affect the function of hBAT1
through the mobilization of second-messenger systems
leading to the activation of PKA or tyrosine kinases.
Some hormones are known to activate second-messenger
systems in tubular epithelial cells. For example, parathy-
roid hormone activates PKA through the mobilization of
cAMP in proximal tubules [50], and dopamine stimulates
PKC in proximal tubules by activating dopamine D1
receptors [51]. Further studies are required to determine
whether hBAT1 function is regulated in vivo by phos-
phorylation through the hormonal stimulation of tubular
epithelia cells.Fig. 10. Influence of tyrosine kinase inhibition on hBAT1-mediated
cystine transport. The effect of tyrosine kinase inhibitor genistein was In the present study, we demonstrated that the human
examined on the hBAT1-mediated [14C]l-cystine uptake. Values are
cystinuria-related transporter formed by heterodimeri-expressed as a percentage of control [14C]l-cystine uptake (1448 6 129
pmol/mg protein/min) measured after the preincubation of cells with zation of hBAT1 and hrBAT in fact exhibits the functional
0.1% DMSO without genistein. The treatment with genistein (20 min) properties of a transporter subserving the amino acid
increased the [14C]l-cystine uptake (100 mmol/L) in a dose-dependent
transport system b0,1, as expected from the observationsfashion (**P , 0.01).
for rat and mouse BAT1/b0,1AT. Because mutations of
either BAT1/b0,1AT or rBAT result in an impairment of
the functional expression of the transporter leading to
The role of phosphorylation of organic solute trans- cystinuria, we conclude that the system b0,1 transporter is
porters has not been thoroughly examined even though crucial for the reabsorption of cystine in human proximal
protein kinase-dependent phosphorylation sites are pre- tubules.
dicted for most of the transporters. As shown in Figure
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14C-cystine uptake (Fig. 8A). The effect of db-cAMP was
This work was supported in part by grants from the Ministry of
inhibited by the PKA-specific inhibitor, suggesting that Education, Science, Sports and Culture of Japan (Grants-in-Aid for
Scientific Research and High-Tech Research Center), the PromotionPKA-dependent phosphorylation of hBAT1 protein leads
and Mutual Aid Corporation for Private Schools of Japan, the Japanto a decreased transport rate (Fig. 8B). In the hBAT1
Science and Technology Corporation, the Uehara Memorial Founda-
sequence, a single PKA phosphorylation site is predicted tion, the Toyota Physical and Chemical Research Institute, and the
at threonine 350 (Fig. 1). Although the SOSUI algorithm Japan Foundation for Applied Enzymology. The authors are grateful
to Hisako Ohba and Michi Takahashi for technical assistance. Thepredicted threonine 350 to be located at the intracellular
authors also thank SeeDNA Biotech for help with the FISH experi-edge of the putative ninth transmembrane domain, it is ment. Anti-BAT1 antibody was supplied by Kumamoto Immunochem-
still possible that this amino acid residue located adjacent ical Laboratory Co., Ltd. (Kumamoto, Japan). The nucleotide se-
quence for hBAT1 has been submitted to the GenBank/EMBL/DDBJto hydrophilic residues (arginine 347 and arginine 348)
Data Bank with an accession number AB033548.is a part of the intracellular loop that can be phosphory-
lated by PKA. In contrast, PMA and staurosporin had no Reprint requests to Yoshikatsu Kanai, M.D., Department of Pharma-
cology and Toxicology, Kyorin University School of Medicine, 6-20-2significant effect of hBAT1-mediated 14C-cystine uptake,
Shinkawa, Mitaka, Tokyo 181-8611, Japan.indicating that PKC-dependent phosphorylation is not
involved in the regulation of the transport activity even
REFERENCESthough some PKC-dependent phosphorylation sites
1. McKusick VA: Cystiuria, in Mendelian Inheritance in Man: Catalogwere predicted in the putative intracellular domains.
of Autosomal Dominant, Autosomal Recessive, and X-Linked Phe-In the family of amino acid transporters associated
notypes (9th ed), Baltimore and London, Johns Hopkins University
with type II membrane glycoproteins (LAT family) Press, 1990, pp 1128–1129
2. Segal S, Thier SO: Cystiuria, in The Molecular and Metabolic[25, 35], the tyrosine kinase-dependent phosphorylation
Basis of Inherited Disease, edited by Seriver CR, Beaudet AL,site corresponding to tyrosine 99 of hBAT1 is conserved
Sly WS, Valle D, New York, McGraw-Hill, 1995, pp 3581–3601
among BAT1/b01AT, LAT1, LAT2, and Asc-1 [35]. In 3. Ito H, Murakami M, Miyauchi T et al: The incidence of cystinuria
in Japan. J Urol 129:1012–1014, 1982the present study, we show that the tyrosine kinase inhib-
Mizoguchi et al: Human cystinuria-related transporter1832
4. Akakura K, Egoshi K, Ueda T et al: The long-term outcome of 27. Pfeiffer R, Loffing J, Rossier G et al: Luminal heterodimeric
amino acid transporter defective in cystinuria. Mol Biol Cell 10:cystinuria in Japan. Urol Int 61:86–89, 1998
5. Rosenberg L, Downing S, Durant J, Segal S: Cystinuria biochem- 4135–4147, 1999
28. Kanai Y, Segawa H, Miyamoto K et al: Expression cloning andical evidence of three genetically distinct diseases. J Clin Invest
45:365–371, 1966 characterization of a transporter for large neutral amino acids
activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem6. Wells RG, Hediger MA: Cloning of a rat kidney cDNA that
stimulates dibasic and neutral amino acid transport and has se- 273:23629–23632, 1998
29. Mastroberardino L, Spindler B, Pfeiffer R et al: Amino-acidquence similarity to glucosidases. Proc Natl Acad Sci USA 89:5596–
5600, 1992 transport by heterodimers of 4F2hc/CD98 and members of perme-
ase family. Nature 395:288–291, 19987. Bertran J, Werner A, Moore ML et al: Expression cloning of a
cDNA from rabbit kidney cortex that induces a single transport 30. Pfeiffer R, Rossier G, Spindler B et al: Amino acid transport of
y1l-type by heterodimers of 4F2hc/CD98 and members of thesystem for cystine and dibasic and neutral amino acids. Proc Natl
Acad Sci USA 89:5601–5605, 1992 glycoprotein-associated amino acid transporter family. EMBO J
18:49–57, 19998. Tate SS, Yan N, Udenfriend S: Expression cloning of a Na1-
independent neutral amino acid transporter from rat kidney. Proc 31. Torrents D, Estevez R, Pineda M et al: Identification and charac-
terization of a membrane protein (y1L amino acid transporter-1)Natl Acad Sci USA 89:1–5, 1992
9. Lee W-S, Wells RG, Sabbag RV et al: Cloning and chromosomal that associates with 4F2hc to encode the amino acid transport
activity y1L. J Biol Chem 273:32437–32445, 1998localization of a human kidney cDNA involved in cystine, dibasic
and neutral amino acid transport. J Clin Invest 91:1959–1963, 1993 32. Pineda M, Fernandez E, Torrents D et al: Identification of a
membrane protein, LAT-2, that co-expressed with 4F2 heavy chain,10. Bertran J, Werner A, Chillaron J et al: Expression cloning of a
human renal cDNA that induces high affinity transport of l-cystine an l-type amino acid transport activity with broad specificity for
small and large zwitterionic amino acids. J Biol Chem 274:19738–shared with dibasic amino acids in Xenopus oocytes. J Biol Chem
268:14842–14849, 1993 19744, 1999
33. Segawa H, Fukasawa Y, Miyamoto K et al: Identification and11. von Winkle LJ, Campione AL, Gorman JM: Na1-independent
transport of basic and zwitterionic amino acids in mouse blastocysts functional characterization of a Na1-independent neutral amino
acid transporter with broad substrate selectivity. J Biol Chem 274:by a shared system and by processes which distinguish between
these substrates. J Biol Chem 263:3150–3163, 1988 19745–19751, 1999
34. Sato H, Tamba M, Ishii T, Bannai S: Cloning and expression12. Palacin M: A new family of proteins (rBAT and 4F2hc) involved
in cationic and zwitterionic amino acid transport: A tale of two pro- of a plasma membrane cystine/glutamate exchange transporter
composed of two distinct proteins. J Biol Chem 274:11455–11458,teins in search of a transport function. J Exp Biol 196:123–137, 1994
13. Mosckovitz R, Yan N, Heimer E et al: Characterization of the 1999
35. Fukasawa Y, Segawa H, Kim JY et al: Identification and character-rat neutral and basic amino acid transporter utilizing anti-peptide
antibodies. Proc Natl Acad Sci USA 90:4022–4026, 1993 ization of a Na1-independent neutral amino acid transporter that
associates with the 4F2 heavy chain and exhibits substrate selectiv-14. Calonge MJ, Gasparini P, Chillaron J et al: Cystinuria caused
by mutations in rBAT gene involved in the transport of cystine. ity for small neutral d- and l-amino acids. J Biol Chem 275:9690–
9698, 2000Nat Genet 6:420–425, 1994
15. Calonge MJ, Volpini V, Bisceglia L et al: Genetic heterogeneity 36. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning
and functional characterization of a multispecific organic anionin cystinuria: The SLC3A1 gene is linked to type I but not to type
III cystinuria. Proc Natl Acad Sci USA 92:9667–9671, 1995 transporter from human kidney. Am J Physiol 276:F122–F128, 1999
37. Utsunomiya-Tate N, Endou H, Kanai Y: Cloning and functional16. Gasparini P, Calonge MJ, Bisceglia L et al: Molecular genetics
of cystinuria: Identification of four new mutations and seven poly- characterization of a system ASC-like Na1-dependent neutral
amino acid transporter. J Biol Chem 271:14883–14890, 1996morphisms, and evidence for genetic heterogeneity. Am J Hum
Genet 57:781–788, 1995 38. Hirokawa T, Boon-Chieng S, Mitaku S: SOSUI: Classification
and secondary structure prediction system for membrane proteins.17. Pras E, Raben N, Golomb E et al: Mutations in the SLC3A1
transporter gene is cystinuria. Am J Hum Genet 56:1297–1303, 1995 Bioinformatics 14:378–379, 1998
39. Heng HHQ, Squire J, Tsui L-C: High resolution mapping of18. Miyamoto K, Katai K, Tatsumi S et al: Mutations of the basic
amino acid transporter gene associated with cystinuria. Biochem mammalian genes by in situ hybridization to free chromosome.
Proc Natl Acad Sci USA 89:9509–9513, 1992J 310:951–955, 1995
19. Bisceglia L, Calonge MJ, Dello Strologo L et al: Molecular 40. Heng HHQ, Tsui L-C: Modes of DAPI banding and simultane-
ously in situ hybridization. Chromosoma 102:325–332, 1993analysis of the cystinuria disease gene: Identification of four new
mutations, one large deletion and one polymorphism. Hum Genet 41. Hisano S, Haga H, Miyamoto K et al: The basic amino acid trans-
porter (rBAT)-like immunoreactivity in paraventricular and su-98:447–451, 1996
20. Horsford J, Saadi I, Raelson J et al: Molecular genetics of cystinu- praoptic magnocellular neurons of the rat hypothalamus. Brain
Res 710:299–302, 1996ria in French Canadians: Identification of four novel mutations in
type I patients. Kidney Int 49:1401–1406, 1996 42. Gekle M, Mildenberger S, Freudinger R et al: Albumin endocy-
tosis in OK cells: Dependence on actin and micro tubules and21. Saadi I, Chen X-Z, Hediger MA et al: Molecular genetics of
cystinuria: Mutation analysis of SLC3A1 and evidence for another regulation by protein kinases. Am J Physiol 272:F668–F677, 1997
43. Alvaro O, Mennone AB, oyer JL: Role of kinases and phospho-gene in the type I (silent) phenotype. Kidney Int 54:48–55, 1998
22. Egoshi K, Akakura K, Kodama T, Ito H: Identification of five tases in the regulation of fluid secretion and Cl-/HCO32 exchange
cholangiocytes. Am J Physiol 273:G303–G313, 1997novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria.
Kidney Int 57:25–32, 2000 44. Lee H, Suh BC, Kim KT: Feedback regulation of ATP-induced
Ca21 signaling in HL-60 cells is mediated by protein kinase A- and23. Palacin M, Estevez R, Zorzano A: Cystinuria calls for heteromul-
timeric amino acid transporters. Curr Opin Cell Biol 10:455–461, C-mediated changes in capacitive Ca21 entry. J Biol Chem 272:
21831–21838, 19971998
24. Bisceglia L, Calonge MJ, Totaro A et al: Localization, by linkage 45. Verrey F, Jack DL, Paulsen IT et al: New glycoprotein-associated
amino acid transporters. J Membr Biol 172:181–192, 1999analysis, of the cystinuria type III gene to chromosome 19q13.1.
Am J Hum Genet 60:611–616, 1997 46. Rosenberg LE, Durant JL, Holland JM: Intestinal absorption
and renal excretion of cystine and cysteine in cystinuria. N Engl25. Chairoungdua A, Segawa H, Kim JY et al: Identification of an
amino acid transporter associated with the cystinuria-related type J Med 273:1239–1245, 1965
47. Foreman JW, Hwang S-M, Segal S: Transport interactions ofII membrane glycoprotein. J Biol Chem 274:28845–28848, 1999
26. International Cystinuria Consortium: Non-type I cystinuria cystine and dibasic amino acids in isolated rat renal tubules. Metab-
olism 29:53–61, 1980caused by mutations in SLC7A9, encoding a subunit (b0,1AT) of
rBAT. Nat Genet 23:52–57, 1999 48. Chillaron J, Estevez R, Mora C et al: Obligatory amino acid
Mizoguchi et al: Human cystinuria-related transporter 1833
exchange via systems b0,1-like and y1l-like: A tertiary active thyroid hormone stimulation of calcium transport is mediated by
dual signaling mechanisms involving protein kinase A and proteintransport mechanism for renal reabsorption of cystine and dibasic
amino acids. J Biol Chem 271:17761–17770, 1996 kinase C. Endocrinology 137:13–20, 1996
51. Kansra V, Chen C, Lokhandwala MF: Dopamine causes stimula-49. Christensen HN: Role of amino acid transport and countertrans-
port in nutrition and metabolism. Physiol Rev 70:43–77, 1990 tion of protein kinase C in rat renal proximal tubules by activating
dopamine D1 receptors. Eur J Pharmacol 289:391–394, 199550. Friedman PA, Coutermarsh BA, Kennedy SM, Gesek FA: Para-
